SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    International Obesity Task Force (IOTF) 2008. Available at http://www.iotf.org (last accessed January 2009).
  • 2
    Daniels SR. The consequences of childhood overweight and obesity. Future Child 2006; 16: 4767.
  • 3
    Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001; 286: 1195200.
  • 4
    National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report. Circulation 2002; 106: 3143421.
  • 5
    Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. Int J Obes 2002; 26: 42536.
  • 6
    Bloomgarden ZT. Second International Symposium on Triglycerides and HDL: Metabolic Syndrome. Diabetes Care 2005; 28: 257784.
  • 7
    Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005; 81: 35866.
  • 8
    Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 53953.
  • 9
    International Diabetes Federation. The IDF consensus worldwide definition of the Metabolic Syndrome. 2005. Available at http://www.idf.org/home/index.cfm?node=1429 (last accessed January 2009).
  • 10
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998; 317: 70313.
  • 11
    Montani J-P, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes 2002; 2: S2838.
  • 12
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 2002; 287: 257081.
  • 13
    Flack JM, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol 2003; 14: S928.
  • 14
    Rashid P, Leonardi-Bee J. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 27419.
  • 15
    Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. NHS RandD Health Technol Assess 2003; 7.
  • 16
    UK Prospective Diabetes Study Group. Risk factors for myocardial infarction case fatality and stroke case fatality in Type 2 diabetes. UKPDS 66. Diabetes Care 2004; 27: 2017.
  • 17
    Goodman E, Whitaker RC. A prospective study of the role of depression in the development and persistence of adolescent obesity. Pediatrics 2002; 110: 497504.
  • 18
    Wardle J, Waller J, Fox E. Age of onset and body dissatisfaction on obesity. Addict Behav 2002; 27: 56173.
  • 19
    Ackard DM, Neumark-Sztainer D, Story M, Perry C. Overeating among adolescents: prevalence and associations with weight-related characteristics and psychological health. Pediatrics 2003; 111: 6774.
  • 20
    Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, Van Belle G, Kessler RC. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63: 82430.
  • 21
    Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ 1995; 311: 43739.
  • 22
    Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004; 109: 24.
  • 23
    Ello-Martin JA, Ledikwe JH, Rolls BJ. The influence of food portion size and energy density on energy intake: implications for weight management. Am J Clin Nutr 2005; 82: 236S241S.
  • 24
    Sanofi-Aventis to discontinue all clinical trials with rimonabant. Sanofi-Aventis press release, Paris, November 5, 2008. Available at http://en.sanofi-aventis.com/binaries/20081105_rimonabant_en_tem28-22682.pdf (last accessed January 2009).
  • 25
    Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 53741.
  • 26
    Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 60916.
  • 27
    Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 5818.
  • 28
    Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. J Am Med Assoc 2000; 283: 17039.
  • 29
    Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes 1998; 22: S1828.
  • 30
    Halford JCG, Wanninayake SCD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 15968.
  • 31
    Halford JCG, Boyland EJ, Cooper SJ, Dovey TM, Huda MSB, Dourish CT, Dawson GR, Wilding JPH. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 2008; 111.
  • 32
    McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 2419.
  • 33
    Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Draft. Guidance for Industry. Developing products for weight management. 2007. Available at http://www.fda.gov/cder/guidance/7544dft.pdf (last accessed January 2009).
  • 34
    European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guidance on clinical evaluation of medicinal products used in weight control. 2007. Available at http://www.emea.europa.eu (last accessed January 2009).
  • 35
    Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 291523.
  • 36
    Sanofi-Aventis Information Meeting, Paris, February 13, 2007. Available at http://en.sanofi-aventis.com/binaries/070213_PDF_RES2006_slides_media_tcm28-15694.pdf (last accessed January 2009).
  • 37
    Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomised clinical trials. Int J Obes 2002; 26: 26273.
  • 38
    Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005; 6: 21523.
  • 39
    Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 119499.
  • 40
    Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50–71 years old. N Engl J Med 2006; 355: 76378.
  • 41
    Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 202837.
  • 42
    Singh PM, Lindsted KD, Fraser GE. Body weight and mortality among adults who never smoked. Am J Epidermiol 1999; 150: 115264.
  • 43
    Karlsson J, Sjöström L, Sullivan M. Swedish obese subjects (SOS)—an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behaviour after gastric surgery for severe obesity. Int J Obes Relat Metab Disord 1998; 22: 1136.
  • 44
    Sjöström L, Lindross A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 268393.
  • 45
    Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlson J, Lindross A-K, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Ågren G, Carlsson LMS. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 74152.
  • 46
    Merck press release. Merck discontinues development of investigational medicine taranabant for obesity. October 2, 2008. Available at http://www.merck.com/newsroom/press_releases/research_and_development/2008-1002.html (last accessed January 2009).
  • 47
    Acomplia (rimonabant) SPC. Available at http://emc.medicines.org.uk/ (last accessed January 2009).
  • 48
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of diabetes in obese patients. Diabetes Care 2004; 27: 15561.
  • 49
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595607.
  • 50
    World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation 1999. WHO/NCD/NCS/99.2.
  • 51
    Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 123747.
  • 52
    National Cholesterol Education Program. NCEP ATP III: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 248697.
  • 53
    Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: time for a critical appraisal. Diabetes Care 2005; 28: 2289304.
  • 54
    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 769.
  • 55
    Pi-Sunyer X. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10: 97S104S.
  • 56
    Rössner S. Obesity: the disease of the twenty-first century. In J Obes 2002; 26: S24.
  • 57
    Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity. New perspectives and pharmacotherapies. Cardiol Rev 2006; 14: 23858.
  • 58
    Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 50113.
  • 59
    Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with Type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 163745.
  • 60
    Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinson MJ. Effect of metformin in pediatric patients with Type 2 diabetes. A randomized controlled trial. Diabetes Care 2002; 25: 8994.
  • 61
    Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 2808.
  • 62
    Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with Type 2 diabetes. Diabetes Care 2001; 24: 30815.
  • 63
    Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycaemic control in patients with Type 2 diabetes mellitus. A randomised, controlled, double-blind trial. JAMA 1998; 280: 14906.
  • 64
    Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes. The PERISCOPE randomised controlled trial. JAMA 2008; 299: 156173.
  • 65
    Horton ES, Clinginbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in Type 2 diabetes. Diabetes Care 2000; 23: 16605.
  • 66
    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycaemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagons-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004; 27: 133542.
  • 67
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (Exendin-4) on glycaemic control and weight over 30 weeks in sulphonylurea-treated patients with Type 2 diabetes. Diabetes Care 2004; 27: 262835.
  • 68
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (Exendin-4) on glycaemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 2005; 28: 1092100.
  • 69
    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 26327.
  • 70
    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with Type 2 diabetes. Diabetes Care 1998; 21: 128894.
  • 71
    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated Type 2 diabetes. Diabetes Care 2002; 25: 103341.
  • 72
    Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S. Effect of orlistat in overweight and obese patients with Type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 11238.
  • 73
    McNulty SJ, Ur E, Williams G. A randomised trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 12531.
  • 74
    Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with Type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 195760.
  • 75
    Sanchea-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult Hispanic patients with Type 2 diabetes mellitus: a 12-month, randomised, double-blind, placebo-controlled clinical trial. Clin Ther 2004; 26: 142735.
  • 76
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 166072.
  • 77
    Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-Naïve Diabetic Patients. Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycaemic control, body weight, and lipid profile in drug-naïve Type 2 diabetes. Diabetes Care 2008; 31: 216976.
  • 78
    Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated Type 2 diabetes. Diabetes Care 2001; 24: 122632.
  • 79
    Olsson PO, Lindström T. Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with Type 2 diabetes. Diabetes Metab 2002; 28: 2727.
  • 80
    Pi-Sunyer X. The effects of pharmacologic agents for Type 2 diabetes mellitus on body weight. Postgrad Med 2008; 120: 517.
  • 81
    Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 242743.
  • 82
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 197987.
  • 83
    Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Ji H, Thomas W, Bantle JP. Two-year outcome of a combination of weight-loss therapies for Type 2 diabetes. Diabetes Care 2005; 28: 13115.
  • 84
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, RIO Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 138997.
  • 85
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 76175.
  • 86
    Déspres JP, Golay A, Sjostrom L, Rimonabant In Obesity Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 212134.
  • 87
    Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Draft. Guidance for Industry. Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. Available at http://www.fda.gov/cder/guidance/7630dft.htm (last accessed January 2009).
  • 88
    Castelli WP, Anderson K, Wilson PW. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992; 2: 238.
  • 89
    Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13Q21Q.
  • 90
    Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Res 1996; 3: 2139.
  • 91
    Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70: 3H9H.
  • 92
    Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 147581.
  • 93
    Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomised, double-blind, placebo-controlled, multicentre study. Int J Obes 2001; 25: 171321.
  • 94
    Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91: 961–4.
  • 95
    Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomised, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardised diet. Clin Ther 2003; 25: 110722.
  • 96
    Filippatos TD, Kiortsis DN, Liberopoulos EN, Gerogoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 19972006.
  • 97
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001; 142: 48997.
  • 98
    Shepherd J, Cobbe WM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ; for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 13017.
  • 99
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 161522.
  • 100
    Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgiersson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 145360.
  • 101
    Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J; for the Scandinavian Simvastatin Survival Study (4S) Group. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the Metabolic Syndrome. Diabetes Care 2004; 27: 173540.
  • 102
    Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001; 103: 38792.
  • 103
    Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; for the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003; 26: 271321.
  • 104
    Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 72941.
  • 105
    Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 46473.
  • 106
    McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB. LDL-C goal attainment with ezetimibe plus simvastatin co-administration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed 2005; 7: 3.
  • 107
    Merck press release. Merck's investigational CETP-inhibitor, MK-0859 (anacetrapib), produced positive effects on lipids with no observed blood pressure changes in Phase IIb study. October 4, 2007. Available at http://www.merck.com/newsroom/press_releases/research_and_development/2007-1004.html (last accessed January 2009).